Cora N. Sternberg

Also affiliated with Lander Institute, Presbyterian Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 26 papers. Top paper: “Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial”.

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology(2021)10.1016/s1470-2045(21)00004-8

N/A

5.8DataRank · unranked

418 citations

Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano +21 more

Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

Journal of Clinical Oncology(2023)10.1200/jco.23.00573

N/A

2.6DataRank · unranked

69 citations

Charlene Thomas, Oliver Sartor, Michael Sun, Judith Stangl‐Kremser, Mahelia Bissassar +10 more

TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations

(2024)10.1093/oncolo/oyae120

N/A

0.687DataRank · unranked

14 citations

Cora N. Sternberg, Hao Wang, Tingchang Wang, Laura Linville, Catherine H. Marshall +5 more

The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1090

N/A

0.589DataRank · unranked

10 citations

Karim Fizazi, Fred Saad, Kim N. Chi, Mary-Ellen Taplin, Cora N. Sternberg +5 more

Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3089

N/A

0.587DataRank · unranked

49 citations

Ronald de Wit, Yves Fradet, Miguel A. Climent, Daniel P. Petrylak, Jae‐Lyun Lee +26 more

Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5015

N/A

0.515DataRank · unranked

30 citations

Michael Sun, Oliver Sartor, Charlene Thomas, Sharon Singh, Mahelia Bissassar +11 more

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Journal of Clinical Oncology(2023)10.1200/jco.22.02661

N/A

0.510DataRank · unranked

29 citations

Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher J. Logothetis +15 more

Harnessing transcriptionally driven chromosomal instability adaptation to target therapy-refractory lethal prostate cancer

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.100937

N/A

0.510DataRank · unranked

29 citations

Sandra Santasusagna, Perumalraja Kirthika, Michael Xu, Peiyao Li, Marc Carceles‐Cordon +16 more

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.11.014

N/A

0.442DataRank · unranked

18 citations

Fadi Taza, Navonil De Sarkar, Alok K. Tewari, Syed Arsalan Ahmed Naqvi, Irbaz Bin Riaz +32 more

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5560

N/A

0.360DataRank · unranked

10 citations

Joseph R. Osborne, Escarleth Fernandez, Charlene Thomas, Muhammad Junaid Niaz, Amy Ciriaco +10 more

Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5018

N/A

0.360DataRank · unranked

10 citations

Michael Philip Sun, Jones T. Nauseef, Charlene Thomas, Sandra Huicochea Castellanos, Joseph Earl Thomas +12 more

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution

European Urology Oncology(2025)10.1016/j.euo.2025.05.014

N/A

0.269DataRank · unranked

5 citations

Marshall A. Diven, Brady Rippon, Christopher E. Barbieri, Jim C. Hu, Douglas S. Scherr +20 more

Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5100

N/A

0.269DataRank · unranked

5 citations

Joseph R. Osborne, Peter Gregos, Charlene Thomas, Mahelia Bissassar, Sharon Singh +14 more

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.158

N/A

0.176DataRank · unranked

1 citations

Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez +10 more

Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.45

N/A

0.165DataRank · unranked

2 citations

Sukanya Goswami, Muhammad Junaid Niaz, Charlene Thomas, Paul J. Christos, Joseph R. Osborne +10 more

The Interplay between Mutagenesis and Extrachromosomal DNA Shapes Urothelial Cancer Evolution

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.05.07.538753

N/A

0.165DataRank · unranked

2 citations

William F. Hooper, Timothy R. Chu, Heather Geiger, Jennifer Shelton, Minita Shah +21 more

Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17007

N/A

0.104DataRank · unranked

1 citations

Juana Martinez Zuloaga, Kritika Subramanian, Peter Gregos, Mahelia Bissassar, Sharon Singh +13 more

Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.120

N/A

0.104DataRank · unranked

1 citations

Michael Sun, Jones T. Nauseef, Muhammad Junaid Niaz, Dunya Imad, Paul J. Christos +11 more

Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.077

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Benedict Ho, Juana Martinez Zuloaga, Brian D. Gonzalez, Michael Sun +15 more

Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5040

N/A

0DataRank · unranked

0 citations

Emily Nizialek, Jacob E. Berchuck, Panagiotis J. Vlachostergios, Ryan Ashkar, Alexandra Sokolova +14 more

Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5055

N/A

0DataRank · unranked

0 citations

Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg +4 more

Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps216

N/A

0DataRank · unranked

9 citations

Joseph R. Osborne, Matthew C. Dallos, Jones T. Nauseef, Cora N. Sternberg, Peter Gregos +11 more

Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.037

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Michael Sun, Oliver Sartor, Sharon Singh, Mahelia Bissassar +15 more

Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.114

N/A

0DataRank · unranked

24 citations

Joseph R. Osborne, Muhammad Junaid Niaz, Shankar Vallabhajosula, Panagiotis J. Vlachostergios, Charlene Thomas +9 more

Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists

Urology Practice(2024)10.1097/upj.0000000000000740

N/A

0DataRank · unranked

5 citations

Andrew J. Armstrong, Eamonn Rogers, Dany Habr, Jochen Walz, Martin Gleave +9 more

Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer

medRxiv(2025)10.1101/2025.07.01.25330467

N/A

0DataRank · unranked

0 citations

Alexander Martinez‐Fundichely, Sandra Cohen, Metin Balaban, Chen Khuan Wong, Weiling Li +26 more